Interaction of c-myc with transforming growth factor alpha and hepatocyte growth factor in hepatocarcinogenesis.
Double transgenic mice bearing fusion genes consisting of mouse albumin enhancer/promoter-mouse c-myc cDNA and mouse metallothionein 1 promoter-human TGF-alpha cDNA were generated to investigate the interaction of these genes in hepatic oncogenesis and to provide a general paradigm for characterizing the interaction of nuclear oncogenes and growth factors in tumorigenesis. Coexpression of c-myc and TGF-alpha as transgenes in the mouse liver resulted in a tremendous acceleration of neoplastic development in this organ as compared to expression of either of these transgenes alone. The two distinct cellular reactions that occurred in the liver of the double transgenic mice prior to the appearance of liver tumors were dysplastic and apoptotic changes in the existing hepatocytes followed by emergence of multiple focal lesions composed of both hyperplastic and dysplastic cell populations. These observations suggest that the interaction of c-myc and TGF-alpha, during development of hepatic neoplasia contributes to the selection and expansion of the preneoplastic cell populations which consequently increases the probability of malignant conversion. These studies have now been extended to examine the interaction of hepatocyte growth factor (HGF) with c-myc during hepatocarcinogenesis in the transgenic mouse model. While sustained overexpression of c-myc in the liver leads to cancer, coexpression of HGF and c-myc in the liver delayed the appearance of preneoplastic lesions and prevented malignant conversion. Similarly, tumor promotion by phenobarbital was completely inhibited in the c-myc/HGF double transgenic mice whereas phenobarbital was an effective tumor promoter in the c-myc single transgenic mice. The results indicate that HGF may function as a tumor suppressor during early stages of liver carcinogenesis, and suggest the possibility of therapeutic application for this cytokine. Furthermore, we show for the first time that interaction of c-myc with HGF or TGF-alpha results in profoundly different outcomes of the neoplastic process in the liver.
Thorgeirsson
S S
SS
Laboratory of Experimental Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. snorri_thorgeirsson@nih.gov
Santoni-Rugiu
E
E
D000818:Animals; D016588:Anticarcinogenic Agents; D002273:Carcinogens / Q000037:antagonists & inhibitors; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic; D017228:Hepatocyte Growth Factor / Q000502:physiology*; D008113:Liver Neoplasms / Q000209:etiology* / Q000235:genetics; D008114:Liver Neoplasms, Experimental / Q000209:etiology* / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D009374:Neoplasms, Experimental; D010634:Phenobarbital / Q000037:antagonists & inhibitors; D016271:Proto-Oncogene Proteins c-myc / Q000502:physiology*; D016211:Transforming Growth Factor alpha / Q000502:physiology*
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D016271:Proto-Oncogene Proteins c-myc; D016211:Transforming Growth Factor alpha; D017228:Hepatocyte Growth Factor; D010634:Phenobarbital